Bridging the Gap: Index Volume [International Conference on AIDS (12th: 1998: Geneva, Switzerland)]

12th World AIDS Conference

inheritance 9inhibitors 101

-- Keyword

Abstract--

SKeyword

Abstract

mmunity in Kenya/Wife and 'Chira' cultural impedime 24168
1 Vif is an endogenous inhibit or of HIV-1 protease and peptide de 377*/11130
roviral compounds that nuclear localization of HIV-1 genom 12370
cytic pathway blockers HIV infection of astrocytes/Amanti 32212
icarbazone-derivatives cytomegalovirus replication in hum 60651
eness, perceptions and inhibiting issues of positive living among 43344
oach for AIDS therapy/ of HIV-1 reverse transcription b 376*/11124
ency disease - MAIDS/ of lymphoma using ribonucleoti 12356
V-1-infected subjects: by anti-Fas antibodies and type- 21160
modulator murabutide/ of HIV-1 replication in reservoir 22424
adamantane analogue/ of HIV-1 replication by newly de 41205
processing-dependent/ of HIV-1 by CD8+ cells from ser 60414
anism of transdominant of CCR5-mediated HIV-1 infecti 54*/11105
ease inhibitors/In vitro of cytochromes P-450 2D6 and 12382
alysis of LPS-mediated of HIV-1 infection of macrophag 31126
t anti-Candida effect by of Candida aspartyl proteinase/ 31211
face proteins/Specific of T-lymphocyte- and macropha 41182
w synergistic or additive of HIV replication in vitro in com 41195
1 reverse transcriptase associated antibodies that relat 42115
/Evaluation of protease inhibitor-associated hyperglycemia in a u 12395
r to nelfinavir/Protease hyperglycemia: Res 32172
atients failing protease inhibitor-based highly active antiretroviral 32305
ded benefit of protease inhibitor-containing combination therapy 341*/12101
al response to protease regimens according 60812
itor therapy in protease inhibitor-experienced patients/Virologic 12338
navir (SQV) in protease inhibitor-naive patients after 72 weeks/Ri 12295
small molecule CXCR4 inhibitor that blocks T-cell line-tropic HIV- 11117
1 Vif is an endogenous of HIV-1 protease and peptide de 377*/11130
IV-1 during protease treatment or by mutants in the vir 11132
e reverse transcriptase (S-1153) for the treatment of HIV 12214
en BID plus a protease (PI) compared to 3TC 150 ma BI 12220

uals/Study of protease
ectiveness of protease
ve analysis of protease
herapy with a protease
2147 (KNI-764), a novel
ts receiving a protease
nt including a protease
ite prolonged protease
n therapy with protease
dherence to proteinase
sorders due to protease
vir/saquinavir protease
ssociated with protease
IV 1 infection/Protease
ts of a double protease
navir, a novel protease
ontinuation of protease
ailure of initial protease
ectiveness of protease
xperiences in protease
uinavir a weak protease
ane guanosine a novel
f the nonnucleoside RT
er initiation of protease
ssociated with protease
ation (D/C) of protease
ct of indinavir (protease
ntaining dual protease
ure of double protease
ombination in protease
/saquinavir in protease
and double nucleoside
escriptions of protease
nts/Impact of protease
HIV RNA and protease
ent development of RT
ansmission of protease
e reverse transcriptase
m/Nationwide protease
Adherence to protease
ontinuation of protease
ntiviral drugs/Protease
up (PACTG)/Protease
-peptidic HIV protease
e reverse transcriptase
Idren with the protease
wo- and three-protease
ountable HIV protease
ane (AOP)-RANTES as

combination in Europe (SPICE): 290*/12222
(PI) therapy (Rx) following "prote 12231
efficacy among patients failing a 12236
in children and adolescents with 12262
of HIV-1 protease/Anti-HIV-1 act 12270
/Factors associated with progres 12282
(PI)/Salvage therapy with a com 12285
therapy suggests residual viral a 12293
/Virological follow-up of HIV infec 12297
based highly effective antiretrovir 12298
containing regimens/Associated 12299
treatment in a BID regimen as sal 12303
therapy/Onset diabetes mellitus 12308
therapy in 19 children with HIV 1 i 12309
therapy with saquinavir and riton 12313,in combination with zidovudine/3 12321
(PI) therapy in routine clinical pra 12325
(PI) regimen/Efficacy and durabil 12330
therapy in protease inhibitor-exp 12338
use in patients heavily pretreated 12340?/ls saquinavir a weak protease 12348
of HIV-1 replication/(-)-/-D-2,6- 12358
(+)-calanolide A/Combination an 12366
therapy/Changes in body habitu 177*/12373
therapy/Hyperglycemia associat 12387
(PI) therapy: Reasons and risk fa 180*/12443
) on HCV viral load in patients co-i 22269
regimens may have synergistic a 22350
therapy as a salvage therapy for 22375
(PI) naive and pretreated HIV-inf 22390
(PI) experienced patients/Combi 22391
therapy/Durable suppression of 22395
(PI) antiretroviral (AR) drugs: Pat 22396
treatment on body composition a 32177
use associated with weight chan 32180
(RTI) resistance patterns in cere 563*/32284
resistant HIV-1 to a recently infec 32288
after prolonged failure with indina 32308
adherence program/Nationwide 32327
(PI) therapy in clinical practice: U 32337
treatment: A clinical survey/Rea 32353
therapy in HIV-infected children p 32440
(PI) use in women and children tr 32444,in a phase I/II study/The safety, t 293*/41176
of HIV-1/S-1153, a new nonnucl 553*/41181
nelfinavir mesylate/Predictors of 41191
combinations against zidovudine 41201
effective against both wild-type a 555*/41212
of HIV-1 infectivity without impair 59*/41231

of a novel HIV protease JE-2147 (KNI-764) in animals/P 42273
ds to measure protease (PI) and reverse transcriptase inh 42277
ntly receiving protease therapy: Results from a multisite i 413*/42282
reatment with protease (PI) containing regimens: Is it equ 42305
98/Receipt of protease therapy by street-recruited injecti 42309
e/Patterns of protease use by healthcare coverage in th 42310
y containing a protease /Serum lipids changes in HIV-infe 60118
ith initiation of protease therapy/Thromboembolic diseas 60160
tors related to protease (PI) adherence among sexually a 60192
cted patients/Protease (PI) change within a triple antiretr 60321
NA response/Protease adherence and HIV-1 RNA respo 60363
atients failing protease based therapy/Nelfinavir-nevira 60365
CMV retinitis/Protease therapy is associated with longer 60405
perience with protease (PI) use in a large clinical practice 60547
ated goals/A protease support group helps patients incr 60574
al response to protease therapy in HIV-infected patients/ 60703
ts in the era of protease therapy/Elderly HIV-infected pati 60704
omparing two protease (PI) regimens (d4T+3TC+IDV vs. 60791
e therapy with protease (PI) in HIV infected patients/Pred 60805
e spectrum of protease inhibitors-induced lipodistrophy/Expandi 12398
ptor CXCR4 and potent inhibitors of HIV/Bicyclams are selective 57*/11107
e presence of protease in vitro/HIV maturation and stab 11133
confer resistance to RT among drug naive HIV-positive 11168
HIV infection/Protease in children with HIV infection/Pr 12172
esistance to protease in naive patients at the time of pr 12201
ombined with protease (PI) in therapy naive patients/A 12210
e reverse transcriptase (NRTIs) in HIV-infected children 12248
fore and after protease /Mortality and health care costs 441*/12264
cy started on protease (PI) in March 1996/Clinical prog 440*/12266
atients taking protease /Significant increases in serum 12269
ance of HIV-1 protease /Importance of molecular flexibil 12277
k City (NYC)/Protease are associated with declining Al 12280
ailure of other protease (PI)/Limited efficacy of nelfinavi 12281
I therapy with protease /HIV RNA load in blood and sem 12284
rization HIV-1 protease /Peptidic "tongs" constrained by 12289
s and impact/Protease among injecting drug users in A 12291
al response to protease in an HIV clinic cohort/Virologic 12294
avir and other protease in the presence of human serum 12315
ed with use of protease: Prevalence, clinical sequalae a 12319
mbination with protease in the treatment of HIV-infected 12320
eatment with protease in HIV and hepatitis C virus (HC 12326
tes and use of protease /Diabetes and use of protease 12327
cal response/Protease containing regimens: The reaso 12334
ed with other protease (PIs)/In vitro antiviral activity an 12339
h reverse transcriptase /Experiences in protease inhibit 12340
hildren/Use of protease in HIV-infected children/Use of 12344
xperience with protease in HIV/AIDS patients/Experienc 12346
n therapy with protease in HIV(+) patients/Tolerability of 12349
e reverse transcriptase (NRTIs) in HIV infected patients 12350
onucleotide reductase (RRIs) in the murine model of im 12356
es on MKC-442 with RT in long-term culture of HIV-1-inf 12362
ts treated with protease /Metabolic changes in HIV-infec 178*/12375
ntiretroviral protease (PIs) on serum lipids and glucos 12381
nd 3A4 by HIV protease /In vitro inhibition of cytochrome 12382
bolism by HIV protease /Prediction of in vivo impairment 12390
ce (ADH) with protease /Factors related to adherence ( 12400
ssociated with protease and use of corticoids ointment/" 12403
ents receiving protease /Unconventional medicine and 14119
g treated with protease gambling with high risk sex?/Ru 14143
oduction of proteinase results in decreasing incidence 22221
nitis receiving protease /Recurrence of CMV disease in 16*"/22239
uence of HIV protease on hepatitis C viral (HCV) load a 22252
se in the era of protease /Risk of CMV disease in the era 22258
o therapy with protease in clinical practice/Response to 22347
nt with HIV-1 protease /Efficacy of the combination sta 22357
dy in the era of protease /AIDS and palliative care: A nee 22435
ron-a-2B and protease /Interferon-a-2B treatment for c 23146
fectiveness of protease /Cost-effectiveness of protease 24125
oteinase/HIV protease have a direct anti-Candida effec 31211
RNA by use of protease /No difference in HCV viraemia 32111
ts treated with protease /HCV viral load in HCV-HIV-co-i 32113
enia/Effects of protease in HIV-related thrombocytopeni 32138
S/Acquired hemostatic (AHI) in patients with AIDS/Acq 32143
apy including protease (PI)/Reversal of neutropenia in 32149

ment including protease /Progressive multifocal leucoen 32194
pairment with protease based regimens/Regression of 32196
to antiviral nucleoside in short-time pretreated and dru 233*/32282
ve failed prior protease (PIs): A clinical cohort study/HI 229*/32287
des regarding protease among HIV infected patients in 32316
erapy with antiprotease among HIV-infected IDUs in Fra 32359